IONS Q1 2025 Earnings — Ionis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

IONSIonis Pharmaceuticals, Inc.

$13B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$132M+10.1% YoY

Gross Profit

$130M98.9% margin

Operating Income

-$147M-111.6% margin

Net Income

-$147M-111.6% margin

EPS (Diluted)

$-0.93

QoQ Revenue Growth

-41.9%

Cash Flow

Operating Cash Flow

-$151M

Free Cash Flow

-$163M

Stock-Based Comp.

$30M

Balance Sheet

Total Assets

$2.8B

Total Liabilities

$2.3B

Stockholders' Equity

$476M

Cash & Equivalents

$264M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$132M	$119M	+10.1%
Gross Profit	$130M	$117M	+10.9%
Operating Income	-$147M	-$150M	+1.8%
Net Income	-$147M	-$143M	-2.9%

Revenue Segments

Commercial

$76M25%

Royalty

$64M21%

Research and Development Revenue

$55M18%

SPINRAZA Royalties

$48M16%

Collaborative Agreement Revenue

$45M15%

Product Sales, Net

$6M2%

Other Commercial

$6M2%

TEGSEDI and WAYLIVRA

$6M2%